BioLineRx is trading 6.5% down at $2.62 amid broad risk-off selling, with biotech down 4.24% and the Nasdaq down 1.00%.
- September 1, 2026 weakness followed renewed interest-rate, geopolitical and global bond-market concerns.
- The August 31 earnings report showed second-quarter revenue of $0.3 million, below the $0.5 million estimate; BioLineRx also announced a $3.75 million offering.
- BioLineRx gained 7.69% on August 31, so today’s decline appears primarily sector- and macro-driven.